Method and apparatus for detecting independent motion in three-dimensional scenes
    41.
    发明授权
    Method and apparatus for detecting independent motion in three-dimensional scenes 有权
    用于检测立体场景独立运动的方法和装置

    公开(公告)号:US06353678B1

    公开(公告)日:2002-03-05

    申请号:US09614690

    申请日:2000-07-13

    IPC分类号: G06K900

    CPC分类号: G06K9/209 G06T7/285

    摘要: A system and method that detects independently moving objects in 3D scenes which are viewed under camera motion progressively applies constraints to the images to ensure the stability of the constraints. The system first calculates 2D view geometry constraints for a set of images. These constraints are tested to determine if the imaged scene exhibits significant 3D characteristics. If it does, then 3D shape constraints, are applied to the set of images. The 3D shape constraints are themselves constrained by the 2D view geometry constraints. The set of images is then tested to identify areas that are inconsistent with the 2D or 3D constraints. These areas correspond to the moving objects. The 2D view geometry constraints are calculated by computing a dominant image alignment for successive pairs of images and then computing constrained epipolar transformations for the two image pairs. This 2D view geometry is further refined based on a plurality of target point correspondences among the plurality of frames. The epipolar geometry for the point correspondence having a minimum median error is selected as the 2D view geometry of the scene. The 3D shape constraint is a parallax geometry that is calculated by iteratively minimizing errors in a parametric alignment of the images using an estimated parallax geometry.

    摘要翻译: 检测在相机运动中观看的3D场景中的独立运动物体的系统和方法逐渐对图像施加约束以确保约束的稳定性。 系统首先计算一组图像的2D视图几何约束。 测试这些约束以确定成像的场景是否显示出显着的3D特征。 如果是,则3D形状约束被应用于图像集合。 3D形状约束本身受2D视图几何约束的限制。 然后测试该组图像以识别与2D或3D约束不一致的区域。 这些区域对应于移动物体。 通过计算连续图像对的主要图像对准,然后计算两个图像对的受限的对极变换来计算2D视图几何约束。 基于多个帧中的多个目标点对应关系进一步改进该2D视图几何。 选择具有最小中值误差的点对应的对极几何作为场景的2D视图几何。 3D形状约束是通过使用估计的视差几何迭代地最小化图像的参数对齐中的误差来计算的视差几何。

    Multi-view image registration with application to mosaicing and lens distortion correction
    43.
    发明授权
    Multi-view image registration with application to mosaicing and lens distortion correction 失效
    多视图图像配准应用于镶嵌和镜头失真校正

    公开(公告)号:US06173087B2

    公开(公告)日:2001-01-09

    申请号:US08966776

    申请日:1997-11-10

    IPC分类号: G06K936

    摘要: An embodiment of the invention is a system and process for true multi-image alignment that does not rely on the measurements of a reference image being distortion free. For instance, lens distortion is a common imaging phenomenon. When lens distortion is present, none of the images can be assumed to be ideal. In an embodiment of the invention, all the images are modeled as intensity measurements represented in their respective coordinate systems, each of which is related to a reference coordinate system through an interior camera transformation and an exterior view transformation. Motion parameters determined in accordance with an embodiment of the invention dictate the position of the input frames within the reference frame. A reference coordinate system is used, but not a reference image. Motion parameters are computed to warp all input images to a virtual image mosaic in the reference coordinate system of the reference frame. Each pixel in the virtual image mosaic may be predicted by intensities at corresponding pixel positions from more than one image. The error measure, which is the sum of the variances of predicted pixel intensities at each pixel location summed over the virtual image mosaic, is minimized. The embodiment of the invention advantageously maximally uses information present in all images.

    摘要翻译: 本发明的实施例是用于真正的多图像对准的系统和过程,其不依赖于无失真的参考图像的测量。 例如,镜头失真是常见的成像现象。 当存在透镜失真时,不能假定图像是理想的。 在本发明的一个实施例中,所有图像被建模为在它们各自的坐标系中表示的强度测量值,每个坐标系统通过内部照相机变换和外部视图变换与参考坐标系相关。 根据本发明的实施例确定的运动参数指示输入框在参考框架内的位置。 使用参考坐标系,而不是参考图像。 计算运动参数以将所有输入图像扭曲成参考框架的参考坐标系中的虚拟图像马赛克。 可以通过来自多于一个图像的相应像素位置处的强度来预测虚拟图像镶嵌中的每个像素。 误差测量值是在虚拟图像镶嵌中相加的每个像素位置处的预测像素强度的方差之和。 本发明的实施例有利地最大限度地利用存在于所有图像中的信息。

    Combination of BRAF and VEGF Inhibitors
    46.
    发明申请
    Combination of BRAF and VEGF Inhibitors 审中-公开
    BRAF和VEGF抑制剂的组合

    公开(公告)号:US20130172378A1

    公开(公告)日:2013-07-04

    申请号:US13820834

    申请日:2011-09-02

    申请人: Rakesh Kumar

    发明人: Rakesh Kumar

    IPC分类号: A61K31/506

    摘要: A novel combination comprising the VEGFR inhibitor 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-(3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl)-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of VEGFR and/or B-Raf is beneficial.

    摘要翻译: 包含VEGFR抑制剂5 - [[4 - [(2,3-二甲基-2H-吲唑-6-基)甲基氨基] -2-嘧啶基]氨基] -2-甲基苯磺酰胺或其药学上可接受的盐的新型组合, 与B-Raf抑制剂,特别是N-(3- [5-(2-氨基-4-嘧啶基)-2-(1,1-二甲基乙基)-1,3-噻唑-4-基] -2-氟苯基 )-2,6-二氟苯磺酰胺或其药学上可接受的盐,包含其的药物组合物以及在治疗VEGFR和/或B-Raf的抑制有益的条件下使用这些组合和组合物的方法。

    RULE-BASED DETERMINATION AND VALIDATION IN BUSINESS OBJECT PROCESSING
    47.
    发明申请
    RULE-BASED DETERMINATION AND VALIDATION IN BUSINESS OBJECT PROCESSING 有权
    基于规则的业务对象处理确定和验证

    公开(公告)号:US20130166472A1

    公开(公告)日:2013-06-27

    申请号:US13335430

    申请日:2011-12-22

    IPC分类号: G06Q10/06

    CPC分类号: G06Q10/10 G06Q10/06 H04L67/02

    摘要: A method to model a business object is disclosed. An analysis module analyzes elements of a business object. A modeling module models business object logic based on the elements of the business object. An implementation module implements the modeled business object logic. A repository stores the modeled business object logic. A business object runtime module executes the modeled business object logic.

    摘要翻译: 公开了一种用于建模业务对象的方法。 分析模块分析业务对象的元素。 建模模块基于业务对象的元素来模拟业务对象逻辑。 实现模块实现建模的业务对象逻辑。 存储库存储建模的业务对象逻辑。 业务对象运行时模块执行建模的业务对象逻辑。

    COMBINATION
    48.
    发明申请
    COMBINATION 有权
    组合

    公开(公告)号:US20130109705A1

    公开(公告)日:2013-05-02

    申请号:US13699077

    申请日:2011-05-19

    IPC分类号: A61K31/519 A61K31/517

    摘要: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, or a pharmaceutically acceptable hydrate and/or salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof.

    摘要翻译: 本发明涉及一种治疗人类癌症的方法和用于治疗的药物组合物。 特别地,该方法涉及一种癌症治疗方法,其包括给予N- {3-氯-4 - [(3-氟苄基)氧基]苯基} -6- [5 - ({[2-(甲磺酰基)乙基]氨基 }甲基)-2-呋喃基] -4-喹唑啉胺或其药学上可接受的水合物和/或盐和N- {3- [3-环丙基-5-(2-氟-4-碘 - 苯基氨基) -2,4,7-三氧代-3,4,6,7-四氢-2H-吡啶并[4,3-d]嘧啶-1-基]苯基}乙酰胺或其药学上可接受的盐或溶剂化物 对有需要的人。

    COMBINATION
    49.
    发明申请
    COMBINATION 审中-公开
    组合

    公开(公告)号:US20120322817A1

    公开(公告)日:2012-12-20

    申请号:US13497576

    申请日:2010-09-23

    摘要: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.

    摘要翻译: 本发明涉及一种治疗人类癌症的方法和用于治疗的药物组合物。 特别地,该方法涉及一种癌症治疗方法,其包括给予N- {3- [3-环丙基-5-(2-氟-4-碘 - 苯基氨基)-6,8-二甲基-2,4,7- 三氧代-3,4,6,7-四氢-2H-吡啶并[4,3-d]嘧啶-1-基]苯基}乙酰胺或其药学上可接受的盐或溶剂化物,和N - {(1S)-2 - 氨基-1 - [(3,4-二氟苯基)甲基]乙基} -5-氯-4-(4-氯-1-甲基-1H-吡唑-5-基)-2-呋喃甲酰胺或其药学上可接受的 其盐,需要其的人。

    COMBINATION
    50.
    发明申请
    COMBINATION 审中-公开
    组合

    公开(公告)号:US20120283278A1

    公开(公告)日:2012-11-08

    申请号:US13497580

    申请日:2010-09-23

    摘要: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.

    摘要翻译: 本发明涉及一种治疗人类癌症的方法和用于治疗的药物组合物。 特别地,该方法涉及一种癌症治疗方法,其包括给予N- {3- [3-环丙基-5-(2-氟-4-碘 - 苯基氨基)-6,8-二甲基-2,4,7- 三氧代-3,4,6,7-四氢-2H-吡啶并[4,3-d]嘧啶-1-基]苯基}乙酰胺或其药学上可接受的盐或溶剂化物,和N - {(1S)-2 - 氨基-1 - [(3-氟苯基)甲基]乙基} -5-氯-4-(4-氯-1-甲基-1H-吡唑-5-基)-2-噻吩甲酰胺或其药学上可接受的盐 ,对有需要的人。